Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-22T16:24:02.871Z Has data issue: false hasContentIssue false
  • English
  • Français

A case report of the efficacy and usefulness of asenapine in the treatment of a cancer patient with delirium and aphagia

Published online by Cambridge University Press:  26 December 2018

Kyoko Osawa ,
Satoshi Ukai  and
Toshiyuki Kuriyama
Kyoko Osawa*
Affiliation:
Department of Neuropsychiatry, Wakayama Medical University, Wakayama, Japan Department of Palliative Medicine, Wakayama Medical University Hospital Oncology Center, Wakayama, Japan
Satoshi Ukai
Affiliation:
Department of Neuropsychiatry, Wakayama Medical University, Wakayama, Japan
Toshiyuki Kuriyama
Affiliation:
Department of Palliative Medicine, Wakayama Medical University Hospital Oncology Center, Wakayama, Japan Department of Anesthesiology, Wakayama Medical University, Wakayama, Japan
*
Author for correspondence: Kyoko Osawa, M.D., Ph.D., Department of Neuropsychiatry, Wakayama Medical University, 811-1, Kimiidera, Wakayama, 641-8509Japan. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Controlling hyperactive and mixed delirium is extremely important for the continuation of cancer treatment in palliative care. In general, oral antipsychotics are the first-line drug therapy for delirium; however, oral administration is problematic in patients presenting dysphagia. In this case report, we describe an end-stage cancer patient with aphagia who developed delirium and responded to sublingual antipsychotic asenapine for treating delirium. We also discuss the effectiveness of asenapine in hyperactive delirium as well as its usefulness for treating delirium in palliative care.

Method

A cancer patient with delirium was treated with several oral antipsychotics commonly used to treat delirium but did not respond to any of them. The patient subsequently developed aphagia with progression of the disease. Sublingual asenapine was therefore given to treat delirium.

Result

Asenapine was effective in treating delirium without causing any obvious side effects.

Significance of results

In the present case, asenapine was effective in treating hyperactive delirium that did not respond to commonly used antipsychotics. Because asenapine is a sublingual tablet, it can be used in patients with dysphagia and aphagia. In addition, this drug is anticipated to diminish the burden of end-stage patients from taking oral medications. Furthermore, its management is easier compared with injections, and can therefore also be easily used in homecare patients. Based on these perspectives, asenapine may become an important option for treating delirium in palliative care.

Keywords

Palliative careDeliriumDysphagiaAsenapineSublingual administration
Type
Case Report
Information
Palliative & Supportive Care , Volume 17 , Issue 4 , August 2019 , pp. 488 - 491
Copyright
Copyright © Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allergan USA, Inc (2017) SaphrisⓇ package insert. Irvine: Allergan USA, Inc.Google Scholar
Bond, SM, Dietrich, MS, Shuster, JL Jr., et al. (2012) Delirium in patients with head and neck cancer in the outpatient treatment setting. Supportive Care in Cancer 20, 1023–1030.Google Scholar
Breitbart, W and Alici, Y (2012) Evidence-based treatment of delirium in patients with cancer. Journal of Clinical Oncology 30, 1206–1214.Google Scholar
Breitbart, W, Rosenfeld, B, Roth, A, et al. (1997) The Memorial Delirium Assessment Scale. Journal of Pain and Symptom Management 13, 128–137.Google Scholar
Gerrits, M, de Greef, R, and Peeters, P (2010) Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects. Biopharmaceutics & Drug Disposition 31, 351–357.Google Scholar
Hui, D, Dev, R, and Bruera, E (2016) Neuroleptics in the management of delirium in patients with advanced cancer. Current Opinion in Supportive and Palliative Care 10, 316–323.Google Scholar
Johnson, RJ 3rd (2018) A research study review of effectiveness of treatments for psychiatric conditions common to end-stage cancer patients: Needs assessment for future research and an impassioned plea. BMC Psychiatry 18, 85.Google Scholar
Landolt, HP and Wehrle, R (2009) Antagonism of serotonergic 5-HT2A/2C receptors: Mutual improvement of sleep, cognition and mood? The European Journal of Neuroscience 29, 1795–1809.Google Scholar
Leucht, S, Cipriani, A, Spineliet, L, et al. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 382, 951–962.Google Scholar
Potkin, SG (2011) Asenapine: A clinical overview. Journal of Clinical Psychiatry 72(Suppl. 1), 14–18.Google Scholar
Pratts, M, Citrome, L, Grant, W, et al. (2014) A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatrica Scandinavica 130, 61–68.Google Scholar
Stepanova, E, Grant, B, and Findling, RL (2018) Asenapine treatment in pediatric patients with bipolar i disorder or schizophrenia: A review. Pediatric Drugs 20, 121–134.Google Scholar
Stoner, SC and Pace, HA (2012) Asenapine: A clinical review of a second-generation antipsychotic. Clinical Therapeutics 34, 1023–1040.Google Scholar